JPMorgan Chase & Co. Has $2.32 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

JPMorgan Chase & Co. reduced its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 3.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 98,387 shares of the company’s stock after selling 3,363 shares during the quarter. JPMorgan Chase & Co. owned 0.10% of Dyne Therapeutics worth $2,318,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of DYN. KBC Group NV lifted its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after acquiring an additional 978 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Dyne Therapeutics in the 4th quarter worth about $257,000. Magnetar Financial LLC bought a new position in Dyne Therapeutics in the fourth quarter valued at about $263,000. E Fund Management Co. Ltd. boosted its stake in shares of Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock valued at $279,000 after purchasing an additional 1,249 shares in the last quarter. Finally, Legato Capital Management LLC acquired a new stake in shares of Dyne Therapeutics during the fourth quarter valued at about $305,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $10.79 on Thursday. The firm has a market cap of $1.23 billion, a PE ratio of -3.03 and a beta of 1.21. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $47.45. The business’s 50 day moving average price is $10.90 and its two-hundred day moving average price is $20.01.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. Research analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Activity

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have sold 6,237 shares of company stock worth $77,760. Company insiders own 20.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. JPMorgan Chase & Co. dropped their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price on shares of Dyne Therapeutics in a report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $47.46.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.